The influence of bisoprolol dose on ADP-induced platelet aggregability in patients on dual antiplatelet therapy

Purpose Dual antiplatelet therapy is recommended after acute coronary syndrome or after percutaneous coronary intervention with coronary stent implantation. Many of the patients on dual antiplatelet therapy receive beta-blockers; some of them could have antiaggregatory effect. Bisoprolol is a highly selective adrenoceptor-blocker, which is often used in the settings of percutaneous coronary intervention or acute coronary syndrome in patients on dual antiplatelet therapy. Its antiaggregative effect has not been extensively studied. Therefore, the aim of this study is to investigate the effect of bisoprolol on ADP-induced platelet aggregation in patients on dual antiplatelet therapy. Methods Platelet aggregability has been measured in 100 patients on dual antiplatelet therapy with multiplate analyzer using ADP test in blood samples anticoagulated with heparin. ADP test values have been expressed by arbitrary units/minute. In univariate and multivariate regression analyses, we have investigated the influence of bisoprolol and its dose and also different factors, such as risk factors, concomitant drugs and their dosage, laboratory findings, on ADP test values. Results Univariate regression analysis showed significant correlation between the bisoprolol dose and the ADP test value (P = 0.046, B= 52.55, 95% confidence interval 0.87-104.23), which was also shown in the multivariate regression analysis (P = 0.018; B= 57.011; 95% confidence interval 10.455-103.567). Conclusion We have identified a positive correlation between bisoprolol dose and ADP-induced platelet aggregability in patients on dual antiplatelet therapy. Coron Artery Dis 21:472-476 (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.